Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243409107> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4243409107 endingPage "31" @default.
- W4243409107 startingPage "31" @default.
- W4243409107 abstract "A. In the first year after organ transplantation, recipients are at the greatest risk of developing lymphoproliferative diseases (PTLDs), which are induced most often by Epstein-Barr virus (EBV) infection, and patients should therefore be screened prior to or at the time of transplantation for EBV antibodies. B. In the rare cases (<5%) where the recipient is EBV seronegative, he or she has a 95% likelihood of receiving an organ from an EBV-seropositive donor, which translates into a high risk of primary EBV infection with seroconversion soon after transplantation. In such cases, the recipient should receive a prophylactic antiviral treatment with acyclovir, valacyclovir or ganciclovir, starting at the time of transplant and lasting for at least 3 months. The specific recommendations given for CMV prophylaxis could be applicable in this situation. C. The treatment of PTLD should be based on accurate pathology with extensive cell markers and phenotyping. The treatment modalities are as follows. Reduction of basal immunosuppression in all cases (either maintain only steroids, or decrease by at least 50% the anti-calcineurin drugs and stop other immunosuppressive drugs). In the case of EBV-positive B-cell lymphoma, antiviral treatment with acyclovir, valacyclovir or ganciclovir may be initiated for at least 1 month or according to the blood level of EBV replication when available. In the case of rare lymphomas from the mucosal-associated lymphoid tissue (MALT) with positive Helicobacter pylori, full eradication of H. pylori should be carried out with a validated protocol. Subsequent H. pylori prophylaxis should be implemented to avoid relapse. In the case of CD20-positive lymphomas, treatment with rituximab, a chimeric monoclonal antibody directed against CD20, should be carried out with one i.v. injection per week for 4 weeks. In the case of diffuse lymphomas or improper response to previous treatment, CHOP chemotherapy should be used alone or in combination with rituximab. The CHOP regimen is cyclophosphamide, doxorubicine, vincristine and prednisone. Complete cessation of immunosuppression with or without graft nephrectomy should also be considered." @default.
- W4243409107 created "2022-05-12" @default.
- W4243409107 date "2002-04-01" @default.
- W4243409107 modified "2023-10-13" @default.
- W4243409107 title "IV.5.9 Other risk factors" @default.
- W4243409107 doi "https://doi.org/10.1093/ndt/17.suppl_4.31" @default.
- W4243409107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12091638" @default.
- W4243409107 hasPublicationYear "2002" @default.
- W4243409107 type Work @default.
- W4243409107 citedByCount "12" @default.
- W4243409107 countsByYear W42434091072015 @default.
- W4243409107 countsByYear W42434091072016 @default.
- W4243409107 countsByYear W42434091072017 @default.
- W4243409107 countsByYear W42434091072020 @default.
- W4243409107 countsByYear W42434091072021 @default.
- W4243409107 countsByYear W42434091072022 @default.
- W4243409107 crossrefType "journal-article" @default.
- W4243409107 hasBestOaLocation W42434091071 @default.
- W4243409107 hasConcept C126322002 @default.
- W4243409107 hasConcept C168444539 @default.
- W4243409107 hasConcept C203014093 @default.
- W4243409107 hasConcept C2522874641 @default.
- W4243409107 hasConcept C2776995267 @default.
- W4243409107 hasConcept C2777451964 @default.
- W4243409107 hasConcept C2777965375 @default.
- W4243409107 hasConcept C2779338263 @default.
- W4243409107 hasConcept C2779820661 @default.
- W4243409107 hasConcept C2780252810 @default.
- W4243409107 hasConcept C2909675724 @default.
- W4243409107 hasConcept C2911091166 @default.
- W4243409107 hasConcept C71924100 @default.
- W4243409107 hasConcept C90924648 @default.
- W4243409107 hasConceptScore W4243409107C126322002 @default.
- W4243409107 hasConceptScore W4243409107C168444539 @default.
- W4243409107 hasConceptScore W4243409107C203014093 @default.
- W4243409107 hasConceptScore W4243409107C2522874641 @default.
- W4243409107 hasConceptScore W4243409107C2776995267 @default.
- W4243409107 hasConceptScore W4243409107C2777451964 @default.
- W4243409107 hasConceptScore W4243409107C2777965375 @default.
- W4243409107 hasConceptScore W4243409107C2779338263 @default.
- W4243409107 hasConceptScore W4243409107C2779820661 @default.
- W4243409107 hasConceptScore W4243409107C2780252810 @default.
- W4243409107 hasConceptScore W4243409107C2909675724 @default.
- W4243409107 hasConceptScore W4243409107C2911091166 @default.
- W4243409107 hasConceptScore W4243409107C71924100 @default.
- W4243409107 hasConceptScore W4243409107C90924648 @default.
- W4243409107 hasIssue "90004" @default.
- W4243409107 hasLocation W42434091071 @default.
- W4243409107 hasLocation W42434091072 @default.
- W4243409107 hasOpenAccess W4243409107 @default.
- W4243409107 hasPrimaryLocation W42434091071 @default.
- W4243409107 hasRelatedWork W1597668645 @default.
- W4243409107 hasRelatedWork W195891786 @default.
- W4243409107 hasRelatedWork W2015384101 @default.
- W4243409107 hasRelatedWork W2053296617 @default.
- W4243409107 hasRelatedWork W2057461145 @default.
- W4243409107 hasRelatedWork W2143759877 @default.
- W4243409107 hasRelatedWork W2181395306 @default.
- W4243409107 hasRelatedWork W2531692844 @default.
- W4243409107 hasRelatedWork W4200605501 @default.
- W4243409107 hasRelatedWork W4243409107 @default.
- W4243409107 hasVolume "17" @default.
- W4243409107 isParatext "false" @default.
- W4243409107 isRetracted "false" @default.
- W4243409107 workType "article" @default.